Related Experiment Video
Updated: Jun 16, 2026
05:59
An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
Published on: November 4, 2022
Evaluating the bioavailability and bioequivalence of generic medications
1University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA. HowlandRH@upmc.edu
Journal of Psychosocial Nursing and Mental Health Services
|January 28, 2010
Summary
Generic drugs are approved by the FDA based on bioequivalence, ensuring the same active ingredient absorption rate and extent as brand-name drugs. This means generic medications offer comparable safety and efficacy without requiring new research.
Area of Science:
- Pharmaceutical Sciences
- Drug Regulation
- Pharmacokinetics
Background:
- The U.S. Food and Drug Administration (FDA) approves generic drugs to increase medication accessibility.
- Generic drug approval relies on meeting specific criteria, primarily bioequivalence, rather than replicating extensive clinical trials.
Purpose of the Study:
- To explain the regulatory basis for generic drug approval by the FDA.
- To define and elaborate on the concept of bioequivalence in pharmaceutical regulation.
Main Methods:
- The abstract outlines the legal framework for generic drug approval.
- Key pharmacokinetic parameters, Maximum Drug Concentration (Cmax) and Area Under the Curve (AUC), are identified as critical measures.
Main Results:
- Bioequivalence is established when the Cmax and AUC of a generic drug are within a defined range compared to the reference brand-name drug.
- This ensures comparable rate and extent of active ingredient absorption.
Conclusions:
- Generic drug approval by the FDA hinges on demonstrating bioequivalence, ensuring therapeutic equivalence to brand-name counterparts.
- Patients can find information on generic and alternative drugs in resources like the Orange Book and Drugs@FDA.
Related Concept Videos
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...